The tachykinergic system as avenues for drug intervention

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

This review discusses a family of receptors that interact with a family of small peptides that belong to the tachykinin family. The three subtypes of tachykinin receptors follow the following suggested nomenclature: NK1, NK2 and NK3. These receptors belong to the 7-transmembrane, G-protein coupled family. The NK receptor family has been implicated in a wide range of disorders, cancers, inflammation and neural-related diseases. The tachykinin NK receptors and their ligands have been implicated in solid and hematological tumors. Antagonists to NK receptors have been synthesized and some have been tested in preclinical and Phase II clinical studies. However, in order to be effective for treatment, it is imperative to understand the biology of NK receptor family as well as related molecules. One such molecule is HGFIN, also referred as nmb and osteoactivin. HGFIN is particularly relevant since it has been shown to interact with the high affinity ligand of NK1, substance P. This report discusses promising applications for targeting the NK receptors. The discussion proposes potential mechanisms that could occur when substance P interacts with HGFIN as well as the role of HGFIN when antagonists are used to block the NK receptors. This review is relevant for central and peripheral nervous system drug development and cancer targets and also discusses the indications for current patents.

Original languageEnglish (US)
Pages (from-to)173-180
Number of pages8
JournalRecent Patents on CNS Drug Discovery
Volume7
Issue number2
DOIs
StatePublished - Jan 1 2012

Fingerprint

Tachykinin Receptors
Substance P
Pharmaceutical Preparations
Peripheral Nervous System Agents
Central Nervous System Agents
Ligands
Tachykinins
Neoplasms
Patents
GTP-Binding Proteins
Terminology
Inflammation
Peptides
Clinical Studies

All Science Journal Classification (ASJC) codes

  • Drug Discovery
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

@article{60df4155be9243cea088a1deeed7532f,
title = "The tachykinergic system as avenues for drug intervention",
abstract = "This review discusses a family of receptors that interact with a family of small peptides that belong to the tachykinin family. The three subtypes of tachykinin receptors follow the following suggested nomenclature: NK1, NK2 and NK3. These receptors belong to the 7-transmembrane, G-protein coupled family. The NK receptor family has been implicated in a wide range of disorders, cancers, inflammation and neural-related diseases. The tachykinin NK receptors and their ligands have been implicated in solid and hematological tumors. Antagonists to NK receptors have been synthesized and some have been tested in preclinical and Phase II clinical studies. However, in order to be effective for treatment, it is imperative to understand the biology of NK receptor family as well as related molecules. One such molecule is HGFIN, also referred as nmb and osteoactivin. HGFIN is particularly relevant since it has been shown to interact with the high affinity ligand of NK1, substance P. This report discusses promising applications for targeting the NK receptors. The discussion proposes potential mechanisms that could occur when substance P interacts with HGFIN as well as the role of HGFIN when antagonists are used to block the NK receptors. This review is relevant for central and peripheral nervous system drug development and cancer targets and also discusses the indications for current patents.",
author = "Pranela Rameshwar",
year = "2012",
month = "1",
day = "1",
doi = "10.2174/157488912800673146",
language = "English (US)",
volume = "7",
pages = "173--180",
journal = "Recent Patents on CNS Drug Discovery",
issn = "1574-8898",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

The tachykinergic system as avenues for drug intervention. / Rameshwar, Pranela.

In: Recent Patents on CNS Drug Discovery, Vol. 7, No. 2, 01.01.2012, p. 173-180.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The tachykinergic system as avenues for drug intervention

AU - Rameshwar, Pranela

PY - 2012/1/1

Y1 - 2012/1/1

N2 - This review discusses a family of receptors that interact with a family of small peptides that belong to the tachykinin family. The three subtypes of tachykinin receptors follow the following suggested nomenclature: NK1, NK2 and NK3. These receptors belong to the 7-transmembrane, G-protein coupled family. The NK receptor family has been implicated in a wide range of disorders, cancers, inflammation and neural-related diseases. The tachykinin NK receptors and their ligands have been implicated in solid and hematological tumors. Antagonists to NK receptors have been synthesized and some have been tested in preclinical and Phase II clinical studies. However, in order to be effective for treatment, it is imperative to understand the biology of NK receptor family as well as related molecules. One such molecule is HGFIN, also referred as nmb and osteoactivin. HGFIN is particularly relevant since it has been shown to interact with the high affinity ligand of NK1, substance P. This report discusses promising applications for targeting the NK receptors. The discussion proposes potential mechanisms that could occur when substance P interacts with HGFIN as well as the role of HGFIN when antagonists are used to block the NK receptors. This review is relevant for central and peripheral nervous system drug development and cancer targets and also discusses the indications for current patents.

AB - This review discusses a family of receptors that interact with a family of small peptides that belong to the tachykinin family. The three subtypes of tachykinin receptors follow the following suggested nomenclature: NK1, NK2 and NK3. These receptors belong to the 7-transmembrane, G-protein coupled family. The NK receptor family has been implicated in a wide range of disorders, cancers, inflammation and neural-related diseases. The tachykinin NK receptors and their ligands have been implicated in solid and hematological tumors. Antagonists to NK receptors have been synthesized and some have been tested in preclinical and Phase II clinical studies. However, in order to be effective for treatment, it is imperative to understand the biology of NK receptor family as well as related molecules. One such molecule is HGFIN, also referred as nmb and osteoactivin. HGFIN is particularly relevant since it has been shown to interact with the high affinity ligand of NK1, substance P. This report discusses promising applications for targeting the NK receptors. The discussion proposes potential mechanisms that could occur when substance P interacts with HGFIN as well as the role of HGFIN when antagonists are used to block the NK receptors. This review is relevant for central and peripheral nervous system drug development and cancer targets and also discusses the indications for current patents.

UR - http://www.scopus.com/inward/record.url?scp=84861739086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861739086&partnerID=8YFLogxK

U2 - 10.2174/157488912800673146

DO - 10.2174/157488912800673146

M3 - Review article

C2 - 22472024

AN - SCOPUS:84861739086

VL - 7

SP - 173

EP - 180

JO - Recent Patents on CNS Drug Discovery

JF - Recent Patents on CNS Drug Discovery

SN - 1574-8898

IS - 2

ER -